SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
biotech firesales
An SI Board Since August 2001
Posts SubjectMarks Bans
3661 167 0
Emcee:  dalroi Type:  Moderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2736Exact Sciences (EXAS) off 20% after hours, now that trading has resumed. Their tuck-10/28/2010
2735* Shares down as much as 52 percent (Adds analyst comments, background; updatesIan@SI-10/25/2010
2734>> The other way to play it is ALKS [down about 25%]. << There was scaram(o)uche-10/20/2010
2733Caris & Company downgrades ALKS to Average from Above Average and lowers theIan@SI-10/20/2010
2732Thanks. Sold out of alks a few years ago, always thot it was a pretty good compafred hayes-10/20/2010
2731The other way to play it is ALKS [down about 25%]. This just a few says after tpgo-neil-10/20/2010
2730Don't follow amln but, as typical, this seems way overdone. Acts like nonappfred hayes-10/20/2010
2729OUCH! AMLN down 49% to $10.45 on receipt of CRL from FDA on Bydureon. Bloomberg&pgo-neil-10/20/2010
2728ALXA 1.45, -1.58, -52.15% shares plunged over 50% to $1.44. marketwatch.comJohn McCarthy-10/11/2010
2727Re: ONTY Offering puts it down to the price it was at end of August.D.Lu-9/24/2010
2726Oncothyreon (ONTY) prices a private offering and gets spanked for a 20% loss. tuck-9/24/2010
2725Vical whacked another 20%. There are some who think this failure implies potenttuck-9/24/2010
2724Vical (VICL) off 27% (had been 35%+) on NV1FGF for prevention of limb ischemia, tuck-9/22/2010
2723TTHI down about 25% to $3. level on halting diabetes trial on TT223. Volume is pgo-neil-9/17/2010
2722ARNA with a 9 - 5 vote against approval will likely be in here when it re-opensDave O.-9/16/2010
2721Another post on a private board. The link to the original post was not provided.RMP-9/16/2010
2720I haven't read the briefing documents. We will find out how this turns out RMP-9/16/2010
2719So what? You tend to get a high background rate when your subjects are near thetuck-9/16/2010
2718Of course, nothing showed up in trials; they were at most two years long. The stuck29/16/2010
2717From a poster in a private board. page 42 of the ARNA Briefing document: "RMP-9/16/2010
2716SNIP from comments made by M Muphy NWI newsletter. The cancer issue was in preclRMP-9/15/2010
2715Well, good luck. I assume you mean a committee recommendation. Whatever. The tuck-9/15/2010
2714I suspect Lorqess will get approval tomorrow and picked up some Sept call optionRMP-9/15/2010
2713Renhuang pharma (CBP) off 21% after canceling 3rd q conference call. I know nadtuck-9/15/2010
2712Causing Arena to be off ~40% yesterday. Today another 15%. Still not sure if ttuck-9/15/2010
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News